WINDLASWindlas Biotech Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on WINDLAS — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 18.1% YoY
- • Debt/Equity: 0.06
- • Promoter holding: 66.2%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 39
Bull case
- • Revenue growth: 18.1% YoY
- • Debt/Equity: 0.06
- • Promoter holding: 66.2%
- • Price vs SMA200: above
Bear case
- • Profit growth: -0.2% YoY
- • RSI: 30
- • MACD: bearish
- • 1-month return: -19.3%
Key risks
- • Momentum is fading versus the broader market
- • Profit growth: -0.2% YoY
- • RSI: 30
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹41.20). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.